TSOI .0174 Powerhouse Patent news and Science Magazine article
Therapeutics Solutions International, Inc. , (OTC PINK: TSOI) announced today the filing of a patent application covering the use of its ProJuvenol™ product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol™, to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression.
TSOI "Immuno-Oncology, described by Science Magazine as 'Breakthrough of the Year(1)' offers the possibility of not only killing tumor cells in a non-toxic manner, but also establishing immunological memory, which patrols the body and destroys recurrent tumor cells. While great progress has been made in developing drugs that stimulate the immune system to recognize and kill tumors, a major pitfall of current approaches is that tumors produce chemicals and oxidative stress that suppresses the immune system, thus limiting efficacy of immune therapies," said Timothy Dixon , CEO of Therapeutics Solutions International, Inc.